Literature DB >> 15671718

Percutaneous laser disc decompression in the treatment of discogenic back pain.

William Black1, Arpad S Fejos, Daniel S J Choy.   

Abstract

OBJECTIVE: Our aim was to evaluate the effects of percutaneous laser disc decompression (PLDD) as discogenic pain treatment using the MacNab criteria. BACKGROUND DATA: Discogenic back pain is believed to be produced from tears in the posterior longitudinal ligament and annulus fibrosus. This pain is exacerbated through increases in intradiscal pressure via provocative discograms and transmitted through the sinuvertebral nerve.
MATERIALS AND METHODS: A total of 37 patients were selected based on clinical findings and provocative discograms. These patients underwent PLDD to the affected disc and were interviewed via telephone and outcome evaluated based on the MacNab criteria.
RESULTS: Survey results revealed that 14 patients (44%) reported a good response, 14 (44%) reported a fair response, and four (12.5%) reported a poor response. The 28 patients (88%) who reported a good and fair response were considered to be successful cases.
CONCLUSION: PLDD is a safe, effective, and minimally invasive procedure that can be used to treat patients with discogenic back pain.

Entities:  

Mesh:

Year:  2004        PMID: 15671718     DOI: 10.1089/pho.2004.22.431

Source DB:  PubMed          Journal:  Photomed Laser Surg        ISSN: 1549-5418            Impact factor:   2.796


  2 in total

1.  MR guidance and thermometry of percutaneous laser disc decompression in open MRI: an initial clinical investigation.

Authors:  Florian Streitparth; Tony Hartwig; Thula Walter; Maximilian De Bucourt; Michael Putzier; Patrick Strube; Tina Bretschneider; Patrick Freyhardt; Martin Maurer; Diane Renz; Bernhard Gebauer; Bernd Hamm; Ulf K M Teichgräber
Journal:  Eur Radiol       Date:  2013-05-09       Impact factor: 5.315

2.  Percutaneous laser disc decompression for thoracic disc disease: report of 10 cases.

Authors:  Scott M W Haufe; Anthony R Mork; Morgan Pyne; Ryan A Baker
Journal:  Int J Med Sci       Date:  2010-06-01       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.